Sage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by HC Wainwright

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 127.48% from the stock’s current price.

SAGE has been the topic of a number of other research reports. Robert W. Baird dropped their target price on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday. Royal Bank of Canada decreased their price target on shares of Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 27th. Truist Financial decreased their price target on shares of Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Finally, Baird R W upgraded shares of Sage Therapeutics to a “hold” rating in a research note on Wednesday, May 29th. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $33.55.

Sage Therapeutics Stock Up 5.0 %

SAGE stock opened at $10.99 on Thursday. The firm has a market cap of $661.38 million, a P/E ratio of -1.31 and a beta of 0.90. The company’s 50-day moving average price is $11.30 and its two-hundred day moving average price is $16.92. Sage Therapeutics has a 12 month low of $9.73 and a 12 month high of $37.17.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The business had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The firm’s quarterly revenue was up 139.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.46) earnings per share. Equities analysts predict that Sage Therapeutics will post -6.54 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Lazard Asset Management LLC bought a new position in shares of Sage Therapeutics in the first quarter worth approximately $127,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Sage Therapeutics by 353.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 5,406 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Sage Therapeutics in the second quarter worth $177,000. Virtu Financial LLC purchased a new stake in Sage Therapeutics in the first quarter worth $187,000. Finally, ProShare Advisors LLC lifted its stake in Sage Therapeutics by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 1,130 shares during the period. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.